The European Commission Approves Astellas’ XOSPATA® for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation Detected by Validated Tests, including the Invivoscribe LeukoStrat CDx FLT3 Mutation AssayInvivoscribe Marketing2021-11-14T22:08:08-08:00December 5th, 2019|2019 Press Releases, Press Releases| Read more
Japan’s MHLW Approves Invivoscribe’s LeukoStrat CDx FLT3 Mutation Assay as the CDx for Daiichi Sankyo’s Quizartinib for Treatment of Relapsed/Refractory FLT3-ITD AML. Expands Use to Include Specimens Collected in EDTAInvivoscribe Marketing2021-02-26T19:10:37-08:00June 19th, 2019|2019 Press Releases, Press Releases| Read more
Invivoscribe Submits LeukoStrat CDx FLT3 Mutation Assay both in the US and Japan to Support Daiichi Sankyo Submissions for QuizartinibInvivoscribe Marketing2022-09-23T16:52:06-07:00November 27th, 2018|2018 Press Releases, Press Releases| Read more
Invivoscribe Submits the LeukoStrat CDx FLT3 Mutation Assay to Support Daiichi Sankyo Submission for Quizartinib in JapanInvivoscribe Marketing2021-02-26T19:11:48-08:00November 19th, 2018|2018 Press Releases, Press Releases| Read more
Invivoscribe® Receives Approval in Japan for its LeukoStrat® CDx FLT3 Mutation Assay to Assess Acute Myeloid Leukemia (AML) Patients Eligible for Treatment with Xospata® (gilteritinib fumarate)Invivoscribe Marketing2021-02-26T19:12:02-08:00September 27th, 2018|2018 Press Releases, Press Releases| Read more
Invivoscribe® Releases LeukoStrat® CDx FLT3 Mutation Assay as CE-marked IVD Assay Kit.wmm2021-02-26T19:12:46-08:00August 1st, 2017|2017 Press Releases, Press Releases| Read more
Invivoscribe® Receives FDA Approval for the LeukoStrat® CDx FLT3 Mutation Assay Companion Diagnostic Test for the Selection of Patients for Rydapt® and is the First Companion Diagnostic for AMLwmm2021-02-26T19:13:02-08:00April 28th, 2017|2017 Press Releases, Press Releases| Read more